Liraglutide, an analogue of glucagon-like peptide 1 (GLP-1), was shown to promote significant improvement in liver histology in individuals with biopsy-proven NASH after 48 hours of therapy. This evidence concerns the gene GCG and metabolic dysfunction-associated steatohepatitis.